Milestone Pharmaceuticals is developing Etripamil, a novel, short acting intrana-sally delivered calcium channel blocker for treatment of paroxysmal supraventricular tachycardia.
Milestone Pharmaceuticals is developing Etripamil, a novel, short acting intrana-sally delivered calcium channel blocker for treatment of paroxysmal supraventricular tachycardia.
Milestone Pharmaceuticals is developing Etripamil, a novel, short acting intrana-sally delivered calcium channel blocker for treatment of paroxysmal supraventricular tachycardia.